Latest News on ANIP

Financial News Based On Company


Advertisement
Advertisement

ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells 4,082 Shares of Company Stock

https://www.marketbeat.com/instant-alerts/insider-ani-pharmaceuticals-nasdaq-anip-ceo-sells-4082-shares-of-company-stock-2026-11-18/
ANI Pharmaceuticals CEO Nikhil Lalwani sold 4,082 shares of company stock for approximately $290,475 on November 18th, reducing his stake by 1.23%. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, while analyst ratings on the stock are mixed with an average "Hold" recommendation.

Form 4 ANI Pharmaceuticals Inc: Nikhil Lalwani (Director, PRESIDENT & CEO) For: 16 November

https://uk.investing.com/news/stock-market-news/form-4-ani-pharmaceuticals-inc-nikhil-lalwani-director-president--ceo-for-16-november-93CH-4992061
This article reports on a Form 4 filing for ANI Pharmaceuticals Inc, detailing insider transactions by Nikhil Lalwani, who serves as a Director, President, and CEO. The filing pertains to activities that occurred on November 16. The report was published by Investing.com.

Nikhil Lalwani sold 1,318 ANI Pharmaceuticals (ANIP) shares, then sold another 4,082.

https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-c854ca827098.html
Nikhil Lalwani, President & CEO of ANI Pharmaceuticals Inc. (ANIP), sold a total of 5,400 shares across two transactions in mid-November 2026. He sold 1,318 shares at a weighted-average price of $71.40 on November 16, 2026, and an additional 4,082 shares at $71.16 on November 18, 2026. Both sales were executed under a Rule 10b5-1 trading plan adopted in May 2026.

Director Nikhil Lalwani proposes selling 5,400 shares of ANI Pharmaceuticals (ANIP).

https://www.stocktitan.net/sec-filings/ANIP/144-ani-pharmaceuticals-inc-sec-filing-cf891da234df.html
Nikhil Lalwani, a director and officer at ANI Pharmaceuticals (ANIP), has filed a notice proposing to sell 5,400 common shares with an aggregate market value of $385,776.00, with an approximate sale date of November 16, 2026. These shares were originally acquired as restricted stock awards on March 7, 2026. This proposed sale follows three previous 5,400-share sales on August 25, September 15, and October 15, which were reported as 10b5-1 sales, with the plan adoption date being May 26, 2026.

Form 144 ANI PHARMACEUTICALS For: 15 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-ani-pharmaceuticals-for-15-november-93CH-5705517
This article from Investing.com announces the filing of Form 144 for ANI Pharmaceuticals (ANIP) on November 15. Form 144 is a notice of the intent to sell restricted securities. The article provides only this brief detail, without further explanation or context.
Advertisement

ANI Pharmaceuticals president & CEO Lalwani sells $383,400 in shares By Investing.com

https://uk.investing.com/news/stock-market-news/ani-pharmaceuticals-president--ceo-lalwani-sells-383400-in-shares-93CH-4983117
Nikhil Lalwani, President & CEO of ANI Pharmaceuticals Inc., sold 5,400 shares of the company's common stock for $383,400 on September 15, 2026, through a pre-arranged trading plan. Despite the stock trading near its 52-week low, InvestingPro analysis indicates it remains undervalued. This transaction follows ANI Pharmaceuticals' stronger-than-expected Q3 2026 earnings, though the company reduced its full-year sales guidance for Cortrophin Gel and announced plans for an acquisition.

Form 4 ANI Pharmaceuticals Inc: Nikhil Lalwani (Director, PRESIDENT & CEO) For: 15 September

https://uk.investing.com/news/stock-market-news/form-4-ani-pharmaceuticals-inc-nikhil-lalwani-director-president--ceo-for-15-september-93CH-4983125
This article reports on a Form 4 filing for ANI Pharmaceuticals Inc, detailing an insider transaction by Nikhil Lalwani, who holds the titles of Director, President, and CEO. The filing is specifically for September 15th. The article briefly mentions ANI Pharmaceuticals Inc.'s stock performance (ANIP +0.53%).

Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Company Stock

https://www.marketbeat.com/instant-alerts/insider-insider-selling-ani-pharmaceuticals-nasdaq-anip-vp-sells-500-shares-of-company-stock-2026-11-13/
Meredith Cook, VP at ANI Pharmaceuticals (NASDAQ:ANIP), sold 500 shares of company stock for $35,400 on November 13, 2026, as part of a pre-arranged Rule 10b5-1 plan, retaining 72,924 shares. This transaction follows previous sales in October and September. The company recently surpassed quarterly earnings estimates, reporting EPS of $2.70 against $2.18 expected and revenue of $290.78 million, a 27.6% increase year-over-year.

There May Be Underlying Issues With The Quality Of ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anip/ani-pharmaceuticals/news/there-may-be-underlying-issues-with-the-quality-of-ani-pharm
Despite strong profit numbers, ANI Pharmaceuticals (NASDAQ:ANIP) earnings may have underlying issues. The company's accrual ratio of -0.11 indicates that its statutory earnings were less than its free cash flow, which is generally a positive sign. However, the profit was boosted by US$21m in unusual items, raising concerns about the sustainability of future earnings.

ANI Pharmaceuticals: Egetis Therapeutics Acquisition Valued At $560 Million To Expand Rare Disease Business

https://pulse2.com/ani-pharmaceuticals-egetis-therapeutics-acquisition-valued-at-560-million-to-expand-rare-disease-business/
ANI Pharmaceuticals is acquiring Sweden-based Egetis Therapeutics for approximately $560 million, a move expected to significantly expand its rare disease portfolio and commercial reach. The acquisition includes EMCITATE, a recently approved treatment for a rare genetic disorder, which ANI anticipates could generate over $300 million in peak annual sales. This strategic transaction aligns with ANI's goal of increasing revenue from higher-margin rare disease products, aiming for them to constitute a substantial majority of its revenue by the end of the decade.
Advertisement

ANI Pharmaceuticals makes $560 million bid for Egetis Therapeutics

https://www.bizjournals.com/twincities/news/2026/11/09/ani-pharmaceuticals-to-acquire-egetis-therapeutics.html
ANI Pharmaceuticals has offered approximately $560 million to acquire Sweden-based Egetis Therapeutics. This acquisition aims to strengthen the Baudette-based company's focus on rare diseases, a segment that is experiencing faster growth than its overall business.

Form 4 ANI Pharmaceuticals Inc: Nikhil Lalwani (Director, PRESIDENT & CEO) For: 25 August

https://ca.investing.com/news/stock-market-news/form-4-ani-pharmaceuticals-inc-nikhil-lalwani-director-president--ceo-for-25-august-93CH-4941874
This article reports on a Form 4 filing for ANI Pharmaceuticals Inc, detailing transactions made by Nikhil Lalwani, who serves as a Director, President, and CEO. The filing pertains to activities that occurred on August 25.

Ani Pharmaceuticals CEO Lalwani sells $401,220 in common stock By Investing.com

https://ca.investing.com/news/stock-market-news/ani-pharmaceuticals-ceo-lalwani-sells-401220-in-common-stock-93CH-4941865
Nikhil Lalwani, CEO and Director of ANI Pharmaceuticals Inc., sold 5,400 shares of common stock worth $401,220 on August 25, 2026, through a pre-arranged trading plan. This sale occurred while the stock was down approximately 15% year-to-date and trading near its 52-week low. Despite the stock sale, the company recently reported strong Q3 2026 financial results, surpassing analyst expectations, and announced a planned acquisition to expand its rare-disease portfolio.

Should ANI Pharmaceuticals (ANIP) Look Undervalued As Results Land And Revenue Guidance Narrows?

https://ca.finance.yahoo.com/news/ani-pharmaceuticals-anip-look-undervalued-080916912.html
ANI Pharmaceuticals (ANIP) recently reported its Q3 2026 results and narrowed its full-year revenue guidance. Despite a recent 11% share price slip over 90 days, the stock is considered undervalued by analysts, with a fair value estimate of $105.78 against a recent close of $67.41. The company's expansion of Cortrophin Gel and increased commercial headcount are expected to drive revenue growth, though risks like payer decisions and manufacturing issues could impact performance.

Cortrophin Gel brings in $139M as ANI Pharmaceuticals (ANIP) reports higher Q3 profit.

https://www.stocktitan.net/sec-filings/ANIP/10-q-ani-pharmaceuticals-inc-quarterly-earnings-report-0e2be17f7335.html
ANI Pharmaceuticals reported a significant increase in Q3 2026 revenue, reaching $290.8 million, up from $227.8 million in the previous year, with net income rising to $35.1 million. A major contributor to this growth was Cortrophin Gel, which generated $138.7 million in revenue. The company also saw increased operating cash flow and announced an offer to acquire Egetis Therapeutics, aiming to further expand its Rare Disease business.
Advertisement

ANI Pharmaceuticals Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62923278/ani-pharmaceuticals-q3-2026-earnings-call-transcript
ANI Pharmaceuticals reported Q3 2026 revenues of $290.8 million, up 28% year-over-year, and adjusted EBITDA of $83.3 million, up 40%. The company announced an offer to acquire Egetis Therapeutics for $560 million to boost its rare disease pipeline with Emcitate, a treatment for MCT8 deficiency. Cortrophin Gel net revenues were below expectations at $138.7 million, leading to revised 2026 guidance, but generics revenue grew 11% to $104.5 million.

ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million

https://www.pharmexec.com/view/ani-acquire-egetis-therapeutics-sells-priority-review-voucher-190-million
ANI Pharmaceuticals has made a public offer to acquire Egetis Therapeutics for approximately $560 million, adjusted for estimated net proceeds from a separate priority review voucher sale. This acquisition aims to strengthen ANI's rare disease portfolio, with Egetis's lead product, Emcitate, expected to generate over $300 million in peak sales. Concurrently, Egetis Therapeutics is selling its Rare Pediatric Disease Priority Review Voucher for $190 million, granted after FDA approval of Emcitate.

ANI Pharmaceuticals Offers SEK 5.6B for Egetis

https://grafa.com/en/news/united-states/ani-pharmaceuticals-egetis-acquisition-sek-5-6-billion
ANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million). The acquisition aims to expand ANI's rare disease drug portfolio, with Egetis's EMCITATE treatment expected to achieve peak annual sales exceeding $300 million. Egetis's board has unanimously recommended the offer, and major shareholders have conditionally agreed to accept.

ANI Pharmaceuticals Offers $560 Million to Acquire Egetis Therapeutics, Expand Rare Disease Portfolio

https://www.citybiz.co/article/929766/ani-pharmaceuticals-offers-560-million-to-acquire-egetis-therapeutics-expand-rare-disease-portfolio/
ANI Pharmaceuticals has proposed to acquire Swedish biopharmaceutical company Egetis Therapeutics for approximately $560 million, aiming to significantly expand its rare disease portfolio. This acquisition includes Egetis' lead product, EMCITATE, a recently approved treatment for MCT8 deficiency with an estimated peak annual sales potential exceeding $300 million. The deal, which has been unanimously recommended by Egetis' board and supported by key shareholders, is expected to accelerate ANI's transformation towards higher-margin rare disease products.

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/05/3396206/0/en/ani-pharmaceuticals-reports-third-quarter-2026-financial-results.html
ANI Pharmaceuticals reported strong third-quarter 2026 financial results, with net revenues increasing 27.6% year-over-year to $290.8 million and adjusted non-GAAP EBITDA up 39.8% to $83.3 million. The company narrowed its 2026 total revenue guidance and raised adjusted non-GAAP EBITDA and diluted EPS guidance, reflecting strong performance in its Rare Disease and Generics businesses. Additionally, ANI announced an offer to acquire Egetis Therapeutics, expanding its Rare Disease portfolio.
Advertisement

ANI Pharma to buy Swedish biotech Egetis for $560M

https://seekingalpha.com/news/4666370-ani-pharma-buy-swedish-biotech-egetis
ANI Pharmaceuticals has announced an offer to acquire Swedish biotech Egetis Therapeutics for $560 million. This acquisition aligns with ANI Pharma's strategic goal of generating a significant portion of its revenue from rare disease products by the end of 2030. Egetis's lead product is Emcitate.

ANI Pharmaceuticals Announces Offer to Acquire Egetis

https://www.globenewswire.com/news-release/2026/11/05/3396047/0/en/ani-pharmaceuticals-announces-offer-to-acquire-egetis-therapeutics-expanding-the-scope-and-scale-of-its-rare-disease-business.html
ANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics AB for approximately $560 million. This acquisition aims to expand ANI's rare disease business, leveraging Egetis's lead asset, EMCITATE®, an approved treatment for MCT8 deficiency with an estimated peak sales potential of over $300 million. The deal is unanimously recommended by Egetis's Board and supported by shareholders controlling 42% of its shares.

Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals

https://www.tradingview.com/news/modular_finance:16f0e1f2bb7de:0-statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals/
The Board of Directors of Egetis Therapeutics unanimously recommends shareholders accept ANI Pharmaceuticals' public cash offer of SEK 11.25 per share, valuing the company at approximately SEK 5,304 million. This offer represents significant premiums over recent trading prices and is supported by key shareholders representing 42.2% of outstanding shares. The Board believes the acquisition will enhance the commercialization of EMCITATE in the U.S. and globally, leveraging ANI's established rare disease platform.

About 1 in 70,000 males have a rare genetic disorder. ANI offered $560 million for the company behind its approved treatment.

https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-announces-offer-to-acquire-egetis-therapeutics-h8h2p6no9y38.html
ANI Pharmaceuticals has made a public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million). The acquisition aims to expand ANI's rare disease business by adding EMCITATE, an approved treatment for MCT8 deficiency, which ANI estimates could achieve peak sales of over $300 million with patent protection extending into mid-2045. Egetis's board unanimously recommends the offer, and shareholders representing about 42% of outstanding shares have committed to accept, with the deal contingent on 90% shareholder acceptance and regulatory approvals.

ANI Pharmaceuticals to present at November investor conferences in healthcare sector.

https://pluang.com/en/news-feed/ani-pharmaceuticals-akan-mempresentasikan-di-konferensi-investor-november
ANI Pharmaceuticals announced that its CEO and executive team will present at two investor conferences in November: the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10 and the 2026 Jefferies Global Healthcare Conference on November 17. These presentations will offer insights into the company's strategies and developments in its biopharmaceutical business, which includes rare diseases, generics, and branded products. Investors can access webcasts of the presentations on ANI's website.
Advertisement

ANI Pharmaceuticals CEO Nikhil Lalwani will speak at two November conferences.

https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-to-present-at-upcoming-november-investor-aji1qt0lbxci.html
ANI Pharmaceuticals (ANIP) announced that CEO Nikhil Lalwani and executive leadership would participate in two upcoming investor conferences in November 2026. The company will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10 and the Jefferies Global Healthcare Conference in London on November 17. Live and archived webcasts of the presentations will be available on ANI Pharmaceuticals' investor website.

ANI Pharmaceuticals, Inc. $ANIP Stock Acquired by Profund Advisors LLC

https://www.marketbeat.com/instant-alerts/filing-ani-pharmaceuticals-inc-anip-stock-acquired-by-profund-advisors-llc-2026-11-03/
Profund Advisors LLC significantly increased its stake in ANI Pharmaceuticals (NASDAQ:ANIP) by 443.7% in the third quarter, bringing its total holdings to 22,656 shares valued at $1.65 million. This comes as ANI Pharmaceuticals reported strong quarterly earnings, exceeding EPS estimates and showing a 25.8% year-over-year revenue increase, with fiscal 2026 EPS guidance set between $9.19 and $9.69. Despite recent insider stock sales totaling $2.22 million, analysts maintain a consensus "Hold" rating with an average price target of $99.60.

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

https://www.globenewswire.com/news-release/2026/11/03/3394020/0/en/ani-pharmaceuticals-to-present-at-upcoming-november-investor-conferences.html
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that its President and CEO, Nikhil Lalwani, and other executive team members will present at two upcoming investor conferences in November 2026. The company will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10th and the 2026 Jefferies Global Healthcare Conference in London on November 17th. Webcasts of these presentations will be available on the company's website.

ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4659_QuantitativeReport_1793145600000
Argus has lowered its target price for ANI Pharmaceuticals Inc. (ANIP) to $68.00 from its previous rating, despite the current price being $70.67. The company specializes in developing, manufacturing, and marketing generic prescription pharmaceuticals, including liquid, powder, and oral solid-dose products. The report also mentions other related analyses, including technical assessments and insider picks for various stocks.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Average Price Target of $99.60

https://www.marketbeat.com/instant-alerts/consensus-ani-pharmaceuticals-inc-nasdaq-anip-stock-has-average-price-target-of-9960-2026-11-02/
ANI Pharmaceuticals (NASDAQ:ANIP) has an average "Hold" rating from seven brokerages, with an average 12-month price target of $99.60, significantly higher than its current price of $72.00. The company recently surpassed earnings expectations, reporting $2.21 per share against estimates of $2.04, with revenue increasing by 25.8% year-over-year. While institutional investors hold a substantial 76.05% of the stock, insiders have been selling shares, totaling approximately $2.22 million in the past 90 days.
Advertisement

Form 4 ANI Pharmaceuticals Inc: Stephen P. Carey (SVP & CFO) For: 29 October

https://ng.investing.com/news/stock-market-news/form-4-ani-pharmaceuticals-inc-stephen-p-carey-svp--cfo-for-29-october-93CH-2772653
This article reports on a Form 4 filing for ANI Pharmaceuticals Inc., specifically detailing a transaction by Stephen P. Carey, the Senior Vice President and Chief Financial Officer, related to October 29. The filing provides insight into insider trading activity for the company.

ani pharmaceuticals svp & cfo Stephen Carey sells $207,679 in stock

https://www.investing.com/news/insider-trading-news/ani-pharmaceuticals-svp--cfo-stephen-carey-sells-207679-in-stock-93CH-4989091
Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals Inc. (NASDAQ:ANIP), sold 2,850 shares of common stock for a total of $207,679 on October 29, 2026. This transaction was part of a Rule 10b5-1 trading plan adopted in March 2026, leaving Mr. Carey with 166,143 shares. Despite the sale, InvestingPro considers the stock undervalued with "GREAT" financial health, while recent analyst ratings reflect a mixed outlook on the company's performance, particularly concerning Cortrophin Gel.

Form 4 ANI Pharmaceuticals Inc: Stephen P. Carey (SVP & CFO) For: 29 October

https://ca.investing.com/news/stock-market-news/form-4-ani-pharmaceuticals-inc-stephen-p-carey-svp--cfo-for-29-october-93CH-4919661
This article reports on a Form 4 filing for ANI Pharmaceuticals Inc, specifically detailing a transaction involving Stephen P. Carey, the company's SVP & CFO, on October 29. The brief report highlights insider trading activity for the pharmaceutical company.

Under a trading plan, ANI Pharmaceuticals (ANIP)'s CFO sold shares averaging $72.87.

https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-a5eb733c6520.html
Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals (ANIP), sold 2,850 shares of common stock on October 29, 2026, at a weighted-average price of $72.87 per share. The sales were executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, with individual trades ranging from $72.18 to $73.29. Following this transaction, Carey directly holds 166,143 shares.

Form 144 ANI PHARMACEUTICALS For: 29 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-ani-pharmaceuticals-for-29-october-93CH-4915542
This article from Investing.com announces the filing of Form 144 for ANI Pharmaceuticals (ANIP) on October 29. Form 144 indicates the intent to sell restricted or controlled securities, often by company insiders. The article provides only this brief notification without further details on the transaction.
Advertisement

Officer plans to sell 8,550 shares of ANI Pharmaceuticals (ANIP).

https://www.stocktitan.net/sec-filings/ANIP/144-ani-pharmaceuticals-inc-sec-filing-d47fe795bd60.html
Stephen P. Carey, an officer at ANI Pharmaceuticals, plans to sell 8,550 common shares of ANIP with an aggregate market value of $613,120.50, approximately on October 29, 2026. These shares were acquired through the vesting of restricted stock awards between March 31, 2021, and April 10, 2021. The filing also notes previous 10b5-1 sales by Carey in August and September 2026.

ANI Pharmaceuticals (ANIP) Set to Post Quarterly Earnings on Thursday

https://www.marketbeat.com/instant-alerts/upcoming-ani-pharmaceuticals-anip-set-to-post-quarterly-earnings-on-thursday-2026-10-29/
ANI Pharmaceuticals (ANIP) is scheduled to release its Q3 2026 earnings before market open on Thursday, November 5th. Analysts anticipate earnings of $2.18 per share on $280.26 million in revenue, following a strong Q2 where the company surpassed expectations. The stock currently holds a "Hold" rating from analysts with an average price target of $99.60, while it trades near its 52-week low.

ANI Pharmaceuticals Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-5-ani-pharmaceuticals-inc-stock/
ANI Pharmaceuticals (ANIP) is projected to announce its Q3 2026 earnings on Thursday, November 5, 2026, before the market opens, with a conference call scheduled for 8:00 AM ET. Analysts expect the company to report earnings of $2.18 per share on revenue of $280.26 million, marking a significant increase from the prior-year quarter. The company has a strong track record, having exceeded consensus EPS estimates in its last eight consecutive quarters.

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

https://finance.yahoo.com/healthcare/articles/ani-pharmaceuticals-discuss-third-quarter-105500406.html
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET. The company's President and CEO, CFO, and Head of Rare Disease will host a webcast and conference call to discuss the results. Details for the call and webcast are provided for investors and interested parties.

ANI Pharmaceuticals (NASDAQ:ANIP) Slips Lower: Is Value Hiding Here?

https://kalkinemedia.com/us/stocks/healthcare/ani-pharmaceuticals-nasdaqanip-slips-lower-is-value-hiding-here
ANI Pharmaceuticals (NASDAQ:ANIP), a specialty drugmaker, has seen its shares fall below a key long-term moving average despite exceeding earnings and revenue forecasts in its latest quarter and providing optimistic full-year guidance. The company specializes in niche medicines, including rare disease treatments and complex generics, which offer diversified revenue streams and a competitive moat due to specialized manufacturing. Investors are urged to watch revenue growth and progress toward guidance to determine if the stock's current valuation represents a hidden value opportunity.
Advertisement

Changes in working capital of ANI Pharmaceuticals, Inc. – SWB:BSFA

https://www.tradingview.com/symbols/SWB-BSFA/financials-cash-flow/changes-in-working-capital/
The article, published on TradingView, focuses on the changes in working capital for ANI Pharmaceuticals, Inc., traded on the Stuttgart Stock Exchange under the symbol BSFA. It is presented as a financial data point from FactSet and ICE Data Services. The content is primarily a data reference page rather than an analytical article.

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

https://www.manilatimes.net/2026/10/23/tmt-newswire/globenewswire/ani-pharmaceuticals-to-discuss-third-quarter-2026-financial-results-on-november-5-2026-at-800-am-et/2452684/amp
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET. The company will host a webcast and conference call with its President and CEO, CFO, and Head of Rare Disease to discuss the results. Details for dial-in and webcast access are provided for investors and interested parties.

ANI Pharmaceuticals, Inc. Estimates – NASDAQ:ANIP

https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-estimates/
This article provides an overview of financial actuals and estimates for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time for both annual and quarterly data.

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

https://www.globenewswire.com/news-release/2026/10/23/3387147/0/en/ani-pharmaceuticals-to-discuss-third-quarter-2026-financial-results-on-november-5-2026-at-8-00-a-m-et.html
ANI Pharmaceuticals, Inc. announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET. Company executives, including President and CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz, will host a webcast and conference call to discuss these results. A live and archived webcast will be available on the company's website under the "Investors" section.

ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4659_QuantitativeReport_1792540800000
Argus has raised its target price for ANI Pharmaceuticals Inc. (ANIP) to $69.00. The company, which currently trades at $72.62, develops, manufactures, and markets generic prescription pharmaceuticals, including liquid, powder, and oral solid-dose products. This report was published on October 21, 2026.
Advertisement

ANI Pharmaceuticals launches generic duloxetine capsules

https://www.investing.com/news/company-news/ani-pharmaceuticals-launches-generic-duloxetine-capsules-93CH-4957078
ANI Pharmaceuticals Inc. (NASDAQ:ANIP) has launched generic Duloxetine Delayed-Release Capsules in 20 mg, 30 mg, and 60 mg strengths, which is the generic version of Cymbalta. This move aims to provide a stable supply of a widely used therapy in a limited market. U.S. annual sales for this product totaled approximately $247 million as of August 2026.

ANI Pharmaceuticals launches generic version of Cymbalta

https://www.streetinsider.com/Corporate+News/ANI+Pharmaceuticals+launches+generic+version+of+Cymbalta/27200381.html
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has launched Duloxetine Delayed-Release Capsules, a generic equivalent to Cymbalta, in 20, 30, and 60 mg doses. This move introduces another alternative in the market for a widely used therapy, aiming to ensure a stable supply. Annual U.S. sales for Duloxetine Delayed-Release Capsules were approximately $247 million as of August 2026.

A generic version of a widely used medicine launches in a U.S. market with about $247 million in annual sales.

https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-announces-the-launch-of-duloxetine-delayed-feno021qdj3s.html
ANI Pharmaceuticals (Nasdaq: ANIP) has launched its generic version of Cymbalta, Duloxetine Delayed-Release Capsules, available in 20, 30, and 60 mg strengths. This launch introduces another treatment alternative to a market with limited suppliers, aiming to ensure a stable supply for patients and providers. The U.S. annual sales for Duloxetine Delayed-Release Capsules were approximately $247 million as of August 2026.

ANI Pharmaceuticals launches generic duloxetine capsules By Investing.com

https://ca.investing.com/news/stock-market-news/ani-pharmaceuticals-launches-generic-duloxetine-capsules-93CH-4887987
ANI Pharmaceuticals has launched generic duloxetine delayed-release capsules in 20 mg, 30 mg, and 60 mg strengths, a generic version of Cymbalta. The company aims to provide an alternative for this widely used therapy in a limited market to ensure stable supply. U.S. annual sales for Duloxetine Delayed-Release Capsules were approximately $247 million as of August 2026.

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

https://www.globenewswire.com/news-release/2026/10/19/3383239/0/en/ani-pharmaceuticals-announces-the-launch-of-duloxetine-delayed-release-capsules.html
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has launched Duloxetine Delayed-Release Capsules in 20, 30, and 60 mg dosages, a generic version of Cymbalta®. This launch aims to provide a stable supply of a widely used therapy in a market with limited competitors. U.S. annual sales for Duloxetine Delayed-Release Capsules were approximately $247 million as of August 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement